Illinois Municipal Retirement Fund Acquires 29,143 Shares of Hologic, Inc. $HOLX

Illinois Municipal Retirement Fund raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 20.4% in the third quarter, HoldingsChannel.com reports. The firm owned 172,294 shares of the medical equipment provider’s stock after purchasing an additional 29,143 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Hologic were worth $11,628,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Winnow Wealth LLC bought a new stake in shares of Hologic in the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd raised its holdings in Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 273 shares in the last quarter. Root Financial Partners LLC bought a new stake in shares of Hologic during the 3rd quarter valued at $27,000. SJS Investment Consulting Inc. grew its holdings in shares of Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 362 shares in the last quarter. Finally, Loomis Sayles & Co. L P bought a new position in shares of Hologic in the second quarter worth $33,000. 94.73% of the stock is owned by institutional investors.

Hologic Trading Down 0.2%

Shares of Hologic stock opened at $74.91 on Friday. The firm’s 50 day moving average is $74.89 and its 200 day moving average is $71.49. The firm has a market capitalization of $16.72 billion, a PE ratio of 31.21, a price-to-earnings-growth ratio of 2.24 and a beta of 0.72. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $75.36. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. Hologic’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.87 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HOLX. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and cut their price objective for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Morgan Stanley upped their price target on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Stephens cut shares of Hologic from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $78.00 target price on shares of Hologic in a research note on Wednesday, October 22nd. Two investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $78.42.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.